Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Srinivas Aluri, Kimo Bachiashvili, MD, Anjali Budhathoki, MD, Tushar D Bhagat, PhD, Gaurav S Choudhary, PhD, Shanisha Gordon, Nandini Ramachandra, Kith Pradhan, PhD, Shahina Maqbool, Aditi Shastri, MD, Jung Im Huh, Sunjin Hwang, Kim Seong-Jin, PhD, Hui Zhang, Britta Will, PhD, Amittha Wickrema, PhD, Ulrich G. Steidl, MD PhD, Amit Verma, MBBS

Blood (2019) 134 (Supplement_1): 2990.

https://doi.org/10.1182/blood-2019-127561

Published: 2019

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans

Christine Rivat, Natalia Izotova, Rachel Richardson, MSc, Danilo Pellin, Rachael Hough, Robert Wynn, MD, Kim Champion, Andre Lopes, Sara Ghorashian, FRCPath, PhD, Martin Pule, Adrian J. Thrasher, MBBS, PhD FMedSci, Luca Biasco, PhD, Persis J Amrolia, FRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 52.

https://doi.org/10.1182/blood-2019-125916

Published: 2019

Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Blood (2019) 134 (Supplement_1): 4319.

https://doi.org/10.1182/blood-2019-123331

Published: 2019

Journal Articles

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Xiuli Wang, PhD, Miriam Walter, Ryan Urak, Laura Lim, Vibhuti Vyas, MS, Sally Mokhtari, PhD, Don J. Diamond, PhD, Angelo Cardoso, PhD, John Zaia, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 3247.

https://doi.org/10.1182/blood-2019-131843

Published: 2019

Journal Articles

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Asim Tameez ud din, MD, Muhammad Qudrat Ullah, MD, Muhammad Yasir Anwar, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Zunairah Shah, MBBS, Ahmed Ibrahim, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5579.

https://doi.org/10.1182/blood-2019-123296

Published: 2019

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Chin Hin Ng, MD MRCP, Ashish Bajel, MBBS, FRACP, FRCPA, William YK Hwang, MBBS, FRCP(London), MMed(Int MD, FAMS, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Mark McHale, B.S., PhD, Chih-Yi Hsieh, MD, Hsuan-Jen Shih, MD, Nicola McIntyre, PhD, Jamie Kwek, Wei-Ling Chang, PhD, Bertil Lindmark, MD PhD

Blood (2018) 132 (Supplement 1): 2676.

https://doi.org/10.1182/blood-2018-99-110570

Published: 2018

Journal Articles

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Tammie Yeh, PhD, Greg O'Connor, MS, Justin Cidado, PhD, J. Carl Barrett, PhD

Blood (2018) 132 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2018-99-114948

Published: 2018

Journal Articles

Patients with MDS Demonstrate Reduced Numbers and Impaired Differentiation of CD141 Hi Conventional Dendritic Cells

Pragya Srivastava, PhD, Elizabeth A. Griffiths, MD, Prashant Singh, PhD, Eduardo Cortes Gomez, BS, Eunice S. Wang, MD, LaurieAnn Ford, BS, Jianmin Wang, PhD, Michael J. Nemeth, PhD

Blood (2017) 130 (Supplement 1): 2955.

https://doi.org/10.1182/blood.V130.Suppl_1.2955.2955

Published: 2017

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Martin Felices, PhD, Craig E. Eckfeldt, MD PhD, Todd R Lenvik, Behiye Kodal, Alexander J. Lenvik, Laura Bendzick, Caitlin Ryan, Melissa A. Geller, Sarah Cooley, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 4465.

https://doi.org/10.1182/blood.V130.Suppl_1.4465.4465

Published: 2017

Journal Articles

Emerging T Cell Engineering Approaches: New Targets and New Cell Sources

Gianpietro Dotti, MD

Blood (2017) 130 (Supplement 1): SCI-13.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-13.SCI-13

Published: 2017

Journal Articles

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MDPhD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD PhD

Blood (2016) 128 (22): 3150.

https://doi.org/10.1182/blood.V128.22.3150.3150

Published: 2016

Journal Articles

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Eric Delabesse, PharmD, PhD, Audrey Sarry, Françoise Huguet, MD, Christian Récher, MD PhD

Blood (2016) 128 (22): 1718.

https://doi.org/10.1182/blood.V128.22.1718.1718

Published: 2016

Journal Articles

Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202

Kamira Karen Maharaj, BS, John J. Powers, B.S., Mibel Pabon-Saldana, Renee Fonseca, Alex Achille, BS, Susan Deng, BS, Hari P. Miskin, MS, Dave Maryanski, Eva Sahakian, PhD, Javier Pinilla-Ibarz, MD PhD

Blood (2016) 128 (22): 3236.

https://doi.org/10.1182/blood.V128.22.3236.3236

Published: 2016

Journal Articles

Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy to Prevent Viral Reactivation in Recipients of Allogeneic T Cell Depleted Stem Cell Transplant

Pawel Muranski, MD, Greg Whitehill, BS, Debbie Draper, RN, Eleftheria Koklanaris, RN, Jeanine Superata, RN, Quan Yu, MS, Marianna Sabatino, MD, Steven L. Highfill, PhD, Hanh Khuu, MD, Sarah I Davies, Mark Chang, Upneet Chawla, BS, MD, Alexandros Spyridonidis, MD PhD, Gary Fahle, MT,SM, Sawa Ito, MD PhD, David Stroncek, MD, Minoo Battiwalla, MDMS, John Barrett, MD

Blood (2016) 128 (22): 979.

https://doi.org/10.1182/blood.V128.22.979.979

Published: 2016

Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2016) 128 (22): 4062.

https://doi.org/10.1182/blood.V128.22.4062.4062

Published: 2016

NARROW

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Patients with MDS Demonstrate Reduced Numbers and Impaired Differentiation of CD141 Hi Conventional Dendritic Cells

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Emerging T Cell Engineering Approaches: New Targets and New Cell Sources

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202

Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy to Prevent Viral Reactivation in Recipients of Allogeneic T Cell Depleted Stem Cell Transplant

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only